Alkermes plc (NASDAQ: ALKS) Stock Competitors & Peer Comparison
See ALKS's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for ALKS and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ALKS | $40.85 | +0.15% | 6.9B | 43.00 | $0.95 | N/A |
| TAK | $18.86 | +1.48% | 60B | 13.56 | $1.39 | +3.35% |
| TEVA | $39.19 | -2.56% | 45.6B | 13.38 | $2.93 | N/A |
| HLN | $9.26 | +0.43% | 40.8B | 18.94 | $0.49 | +2.15% |
| ZTS | $71.05 | +1.11% | 29.8B | 10.80 | $6.58 | +2.97% |
| VTRS | $17.83 | +2.35% | 20.8B | 7.08 | $2.52 | +2.69% |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
| ELAN | $22.31 | -0.18% | 11.2B | 21.07 | $1.06 | N/A |
| RDY | $12.25 | -0.41% | 10.2B | 20.09 | $0.61 | +0.68% |
Stock Comparison
Takeda Pharmaceutical Company Limited (NYSE: TAK)
ALKS vs TAK Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, TAK has a market cap of 60B. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while TAK trades at $18.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas TAK's P/E ratio is 13.56. In terms of profitability, ALKS's ROE is +0.04%, compared to TAK's ROE of +0.02%. Regarding short-term risk, ALKS is more volatile compared to TAK. This indicates higher risk in terms of short-term price fluctuations for ALKS.Check TAK's competition here
Teva Pharmaceutical Industries Limited (NYSE: TEVA)
ALKS vs TEVA Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, TEVA has a market cap of 45.6B. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while TEVA trades at $39.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas TEVA's P/E ratio is 13.38. In terms of profitability, ALKS's ROE is +0.04%, compared to TEVA's ROE of +0.09%. Regarding short-term risk, ALKS is less volatile compared to TEVA. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check TEVA's competition here
Haleon plc (NYSE: HLN)
ALKS vs HLN Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, HLN has a market cap of 40.8B. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while HLN trades at $9.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas HLN's P/E ratio is 18.94. In terms of profitability, ALKS's ROE is +0.04%, compared to HLN's ROE of +0.17%. Regarding short-term risk, ALKS is less volatile compared to HLN. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check HLN's competition here
Zoetis Inc. (NYSE: ZTS)
ALKS vs ZTS Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, ZTS has a market cap of 29.8B. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while ZTS trades at $71.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas ZTS's P/E ratio is 10.80. In terms of profitability, ALKS's ROE is +0.04%, compared to ZTS's ROE of +0.69%. Regarding short-term risk, ALKS is less volatile compared to ZTS. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check ZTS's competition here
Viatris Inc. (NASDAQ: VTRS)
ALKS vs VTRS Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, VTRS has a market cap of 20.8B. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while VTRS trades at $17.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas VTRS's P/E ratio is 7.08. In terms of profitability, ALKS's ROE is +0.04%, compared to VTRS's ROE of -0.03%. Regarding short-term risk, ALKS is less volatile compared to VTRS. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check VTRS's competition here
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI)
ALKS vs ITCI Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas ITCI's P/E ratio is -180.64. In terms of profitability, ALKS's ROE is +0.04%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, ALKS is more volatile compared to ITCI. This indicates higher risk in terms of short-term price fluctuations for ALKS.Check ITCI's competition here
Catalent, Inc. (NYSE: CTLT)
ALKS vs CTLT Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas CTLT's P/E ratio is -27.84. In terms of profitability, ALKS's ROE is +0.04%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, ALKS is more volatile compared to CTLT. This indicates higher risk in terms of short-term price fluctuations for ALKS.Check CTLT's competition here
Elanco Animal Health Incorporated (NYSE: ELAN)
ALKS vs ELAN Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, ELAN has a market cap of 11.2B. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while ELAN trades at $22.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas ELAN's P/E ratio is 21.07. In terms of profitability, ALKS's ROE is +0.04%, compared to ELAN's ROE of -0.03%. Regarding short-term risk, ALKS is less volatile compared to ELAN. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check ELAN's competition here
Dr. Reddy's Laboratories Limited (NYSE: RDY)
ALKS vs RDY Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, RDY has a market cap of 10.2B. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while RDY trades at $12.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas RDY's P/E ratio is 20.09. In terms of profitability, ALKS's ROE is +0.04%, compared to RDY's ROE of +0.09%. Regarding short-term risk, ALKS is more volatile compared to RDY. This indicates higher risk in terms of short-term price fluctuations for ALKS.Check RDY's competition here
Lantheus Holdings, Inc. (NASDAQ: LNTH)
ALKS vs LNTH Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, LNTH has a market cap of 6.5B. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while LNTH trades at $99.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas LNTH's P/E ratio is 16.76. In terms of profitability, ALKS's ROE is +0.04%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, ALKS is more volatile compared to LNTH. This indicates higher risk in terms of short-term price fluctuations for ALKS.Check LNTH's competition here
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX)
ALKS vs AMRX Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, AMRX has a market cap of 6.3B. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while AMRX trades at $19.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas AMRX's P/E ratio is 21.97. In terms of profitability, ALKS's ROE is +0.04%, compared to AMRX's ROE of -3.27%. Regarding short-term risk, ALKS is less volatile compared to AMRX. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check AMRX's competition here
Indivior Pharmaceuticals Inc (NASDAQ: INDV)
ALKS vs INDV Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, INDV has a market cap of 4.5B. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while INDV trades at $35.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas INDV's P/E ratio is 9.81. In terms of profitability, ALKS's ROE is +0.04%, compared to INDV's ROE of -2.16%. Regarding short-term risk, ALKS is more volatile compared to INDV. This indicates higher risk in terms of short-term price fluctuations for ALKS.Check INDV's competition here
Regencell Bioscience Holdings Limited (NASDAQ: RGC)
ALKS vs RGC Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, RGC has a market cap of 3.1B. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while RGC trades at $6.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas RGC's P/E ratio is -434.51. In terms of profitability, ALKS's ROE is +0.04%, compared to RGC's ROE of -2.32%. Regarding short-term risk, ALKS is less volatile compared to RGC. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check RGC's competition here
Alvotech (NASDAQ: ALVOW)
ALKS vs ALVOW Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, ALVOW has a market cap of 2.8B. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while ALVOW trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas ALVOW's P/E ratio is 43.76. In terms of profitability, ALKS's ROE is +0.04%, compared to ALVOW's ROE of +0.77%. Regarding short-term risk, ALKS is more volatile compared to ALVOW. This indicates higher risk in terms of short-term price fluctuations for ALKS.Check ALVOW's competition here
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN)
ALKS vs SUPN Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, SUPN has a market cap of 2.5B. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while SUPN trades at $42.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas SUPN's P/E ratio is 13.94. In terms of profitability, ALKS's ROE is +0.04%, compared to SUPN's ROE of -0.10%. Regarding short-term risk, ALKS is less volatile compared to SUPN. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check SUPN's competition here
HUTCHMED (China) Limited (NASDAQ: HCM)
ALKS vs HCM Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, HCM has a market cap of 2.4B. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while HCM trades at $13.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas HCM's P/E ratio is 5.22. In terms of profitability, ALKS's ROE is +0.04%, compared to HCM's ROE of +0.01%. Regarding short-term risk, ALKS is less volatile compared to HCM. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check HCM's competition here
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)
ALKS vs DCPH Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas DCPH's P/E ratio is -11.58. In terms of profitability, ALKS's ROE is +0.04%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, ALKS is more volatile compared to DCPH. This indicates higher risk in terms of short-term price fluctuations for ALKS.Check DCPH's competition here
Perrigo Company plc (NYSE: PRGO)
ALKS vs PRGO Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, PRGO has a market cap of 2.1B. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while PRGO trades at $15.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas PRGO's P/E ratio is 6.17. In terms of profitability, ALKS's ROE is +0.04%, compared to PRGO's ROE of -0.56%. Regarding short-term risk, ALKS is less volatile compared to PRGO. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check PRGO's competition here
Bausch Health Companies Inc. (NYSE: BHC)
ALKS vs BHC Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, BHC has a market cap of 2.1B. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while BHC trades at $5.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas BHC's P/E ratio is 1.45. In terms of profitability, ALKS's ROE is +0.04%, compared to BHC's ROE of +0.89%. Regarding short-term risk, ALKS is less volatile compared to BHC. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check BHC's competition here
Avadel Pharmaceuticals plc (NASDAQ: AVDL)
ALKS vs AVDL Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while AVDL trades at $21.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, ALKS's ROE is +0.04%, compared to AVDL's ROE of +0.05%. Regarding short-term risk, ALKS is more volatile compared to AVDL. This indicates higher risk in terms of short-term price fluctuations for ALKS.Check AVDL's competition here
Trulieve Cannabis Corp. (NYSE: TRLV)
ALKS vs TRLV Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, TRLV has a market cap of 2.1B. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while TRLV trades at $12.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas TRLV's P/E ratio is -4.96. In terms of profitability, ALKS's ROE is +0.04%, compared to TRLV's ROE of -0.44%. Regarding short-term risk, ALKS is less volatile compared to TRLV. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check TRLV's competition here
Alvotech (NASDAQ: ALVO)
ALKS vs ALVO Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, ALVO has a market cap of 1.9B. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while ALVO trades at $5.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas ALVO's P/E ratio is -9.75. In terms of profitability, ALKS's ROE is +0.04%, compared to ALVO's ROE of +0.77%. Regarding short-term risk, ALKS is less volatile compared to ALVO. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check ALVO's competition here
Embecta Corp. (NASDAQ: EMBCV)
ALKS vs EMBCV Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas EMBCV's P/E ratio is N/A. In terms of profitability, ALKS's ROE is +0.04%, compared to EMBCV's ROE of -0.19%. Regarding short-term risk, ALKS is less volatile compared to EMBCV. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check EMBCV's competition here
Dynavax Technologies Corporation (NASDAQ: DVAX)
ALKS vs DVAX Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while DVAX trades at $15.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas DVAX's P/E ratio is -41.89. In terms of profitability, ALKS's ROE is +0.04%, compared to DVAX's ROE of -0.10%. Regarding short-term risk, ALKS is more volatile compared to DVAX. This indicates higher risk in terms of short-term price fluctuations for ALKS.Check DVAX's competition here
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP)
ALKS vs ANIP Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, ANIP has a market cap of 1.7B. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while ANIP trades at $74.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas ANIP's P/E ratio is 9.00. In terms of profitability, ALKS's ROE is +0.04%, compared to ANIP's ROE of +0.19%. Regarding short-term risk, ALKS is less volatile compared to ANIP. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check ANIP's competition here
Taro Pharmaceutical Industries Ltd. (NYSE: TARO)
ALKS vs TARO Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas TARO's P/E ratio is 30.05. In terms of profitability, ALKS's ROE is +0.04%, compared to TARO's ROE of +0.03%. Regarding short-term risk, ALKS is more volatile compared to TARO. This indicates higher risk in terms of short-term price fluctuations for ALKS.Check TARO's competition here
Eton Pharmaceuticals, Inc. (NASDAQ: ETON)
ALKS vs ETON Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, ETON has a market cap of 1.6B. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while ETON trades at $57.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas ETON's P/E ratio is 151.79. In terms of profitability, ALKS's ROE is +0.04%, compared to ETON's ROE of +0.40%. Regarding short-term risk, ALKS is less volatile compared to ETON. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check ETON's competition here
Phibro Animal Health Corporation (NASDAQ: PAHC)
ALKS vs PAHC Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, PAHC has a market cap of 1.4B. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while PAHC trades at $34.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas PAHC's P/E ratio is 11.76. In terms of profitability, ALKS's ROE is +0.04%, compared to PAHC's ROE of +0.29%. Regarding short-term risk, ALKS is less volatile compared to PAHC. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check PAHC's competition here
Cronos Group Inc. (NASDAQ: CRON)
ALKS vs CRON Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, CRON has a market cap of 1.2B. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while CRON trades at $3.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas CRON's P/E ratio is 17.10. In terms of profitability, ALKS's ROE is +0.04%, compared to CRON's ROE of +0.06%. Regarding short-term risk, ALKS is less volatile compared to CRON. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check CRON's competition here
Harrow Health, Inc. (NASDAQ: HROW)
ALKS vs HROW Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, HROW has a market cap of 1.2B. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while HROW trades at $33.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas HROW's P/E ratio is -33.40. In terms of profitability, ALKS's ROE is +0.04%, compared to HROW's ROE of -1.04%. Regarding short-term risk, ALKS is less volatile compared to HROW. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check HROW's competition here
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH)
ALKS vs AMPH Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, AMPH has a market cap of 1.2B. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while AMPH trades at $26.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas AMPH's P/E ratio is 8.92. In terms of profitability, ALKS's ROE is +0.04%, compared to AMPH's ROE of +0.10%. Regarding short-term risk, ALKS is less volatile compared to AMPH. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check AMPH's competition here
Pacira BioSciences, Inc. (NASDAQ: PCRX)
ALKS vs PCRX Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, PCRX has a market cap of 988.1M. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while PCRX trades at $25.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas PCRX's P/E ratio is 9.66. In terms of profitability, ALKS's ROE is +0.04%, compared to PCRX's ROE of +0.02%. Regarding short-term risk, ALKS is less volatile compared to PCRX. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check PCRX's competition here
PetIQ, Inc. (NASDAQ: PETQ)
ALKS vs PETQ Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas PETQ's P/E ratio is 83.73. In terms of profitability, ALKS's ROE is +0.04%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, ALKS is more volatile compared to PETQ. This indicates higher risk in terms of short-term price fluctuations for ALKS.Check PETQ's competition here
Collegium Pharmaceutical, Inc. (NASDAQ: COLL)
ALKS vs COLL Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, COLL has a market cap of 730.7M. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while COLL trades at $22.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas COLL's P/E ratio is 2.83. In terms of profitability, ALKS's ROE is +0.04%, compared to COLL's ROE of +0.16%. Regarding short-term risk, ALKS is less volatile compared to COLL. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check COLL's competition here
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD)
ALKS vs IRWD Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, IRWD has a market cap of 679.9M. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while IRWD trades at $4.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas IRWD's P/E ratio is 5.29. In terms of profitability, ALKS's ROE is +0.04%, compared to IRWD's ROE of -0.57%. Regarding short-term risk, ALKS is less volatile compared to IRWD. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check IRWD's competition here
Aquestive Therapeutics, Inc. (NASDAQ: AQST)
ALKS vs AQST Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, AQST has a market cap of 587.2M. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while AQST trades at $4.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas AQST's P/E ratio is -7.20. In terms of profitability, ALKS's ROE is +0.04%, compared to AQST's ROE of +2.44%. Regarding short-term risk, ALKS is less volatile compared to AQST. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check AQST's competition here
BioDelivery Sciences International, Inc. (NASDAQ: BDSI)
ALKS vs BDSI Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas BDSI's P/E ratio is 6.82. In terms of profitability, ALKS's ROE is +0.04%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, ALKS is more volatile compared to BDSI. This indicates higher risk in terms of short-term price fluctuations for ALKS.Check BDSI's competition here
Evotec SE (NASDAQ: EVO)
ALKS vs EVO Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, EVO has a market cap of 554.2M. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while EVO trades at $1.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas EVO's P/E ratio is -2.20. In terms of profitability, ALKS's ROE is +0.04%, compared to EVO's ROE of -0.27%. Regarding short-term risk, ALKS is less volatile compared to EVO. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check EVO's competition here
Glass House Brands Inc (NYSE: GLAS)
ALKS vs GLAS Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, GLAS has a market cap of 551.3M. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while GLAS trades at $6.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas GLAS's P/E ratio is -12.72. In terms of profitability, ALKS's ROE is +0.04%, compared to GLAS's ROE of -0.51%. Regarding short-term risk, ALKS is less volatile compared to GLAS. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check GLAS's competition here
Evolus, Inc. (NASDAQ: EOLS)
ALKS vs EOLS Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, EOLS has a market cap of 524.9M. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while EOLS trades at $7.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas EOLS's P/E ratio is -25.24. In terms of profitability, ALKS's ROE is +0.04%, compared to EOLS's ROE of +1.23%. Regarding short-term risk, ALKS is less volatile compared to EOLS. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check EOLS's competition here
Kamada Ltd. (NASDAQ: KMDA)
ALKS vs KMDA Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, KMDA has a market cap of 503.1M. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while KMDA trades at $8.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas KMDA's P/E ratio is 22.95. In terms of profitability, ALKS's ROE is +0.04%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, ALKS is more volatile compared to KMDA. This indicates higher risk in terms of short-term price fluctuations for ALKS.Check KMDA's competition here
Alpha Teknova, Inc. (NASDAQ: TKNO)
ALKS vs TKNO Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, TKNO has a market cap of 500.2M. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while TKNO trades at $9.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas TKNO's P/E ratio is -30.10. In terms of profitability, ALKS's ROE is +0.04%, compared to TKNO's ROE of -0.25%. Regarding short-term risk, ALKS is less volatile compared to TKNO. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check TKNO's competition here
Tilray Brands, Inc. (NASDAQ: TLRY)
ALKS vs TLRY Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, TLRY has a market cap of 461.9M. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while TLRY trades at $4.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas TLRY's P/E ratio is -3.81. In terms of profitability, ALKS's ROE is +0.04%, compared to TLRY's ROE of -0.08%. Regarding short-term risk, ALKS is less volatile compared to TLRY. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check TLRY's competition here
Canopy Growth Corporation (NASDAQ: CGC)
ALKS vs CGC Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, CGC has a market cap of 397.5M. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while CGC trades at $0.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas CGC's P/E ratio is -2.11. In terms of profitability, ALKS's ROE is +0.04%, compared to CGC's ROE of -0.33%. Regarding short-term risk, ALKS is less volatile compared to CGC. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check CGC's competition here
Emergent BioSolutions Inc. (NYSE: EBS)
ALKS vs EBS Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, EBS has a market cap of 350.6M. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while EBS trades at $6.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas EBS's P/E ratio is 4.72. In terms of profitability, ALKS's ROE is +0.04%, compared to EBS's ROE of -0.36%. Regarding short-term risk, ALKS is less volatile compared to EBS. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check EBS's competition here
Alimera Sciences, Inc. (NASDAQ: ALIM)
ALKS vs ALIM Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas ALIM's P/E ratio is 5.28. In terms of profitability, ALKS's ROE is +0.04%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, ALKS is more volatile compared to ALIM. This indicates higher risk in terms of short-term price fluctuations for ALKS.Check ALIM's competition here
Landec Corporation (NASDAQ: LNDC)
ALKS vs LNDC Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas LNDC's P/E ratio is -4.04. In terms of profitability, ALKS's ROE is +0.04%, compared to LNDC's ROE of +6.44%. Regarding short-term risk, ALKS is less volatile compared to LNDC. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check LNDC's competition here
Aurora Cannabis Inc. (NASDAQ: ACB)
ALKS vs ACB Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, ACB has a market cap of 254M. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while ACB trades at $4.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas ACB's P/E ratio is -2.96. In terms of profitability, ALKS's ROE is +0.04%, compared to ACB's ROE of -0.21%. Regarding short-term risk, ALKS is less volatile compared to ACB. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check ACB's competition here
SIGA Technologies, Inc. (NASDAQ: SIGA)
ALKS vs SIGA Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, SIGA has a market cap of 247.4M. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while SIGA trades at $3.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas SIGA's P/E ratio is 12.78. In terms of profitability, ALKS's ROE is +0.04%, compared to SIGA's ROE of -0.02%. Regarding short-term risk, ALKS is less volatile compared to SIGA. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check SIGA's competition here
Shineco, Inc. (NASDAQ: TYHT)
ALKS vs TYHT Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas TYHT's P/E ratio is -1.61. In terms of profitability, ALKS's ROE is +0.04%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, ALKS is less volatile compared to TYHT. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check TYHT's competition here
Cardiol Therapeutics Inc. (NASDAQ: CRDL)
ALKS vs CRDL Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, CRDL has a market cap of 197.1M. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while CRDL trades at $1.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas CRDL's P/E ratio is -6.81. In terms of profitability, ALKS's ROE is +0.04%, compared to CRDL's ROE of -1.94%. Regarding short-term risk, ALKS is less volatile compared to CRDL. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check CRDL's competition here
Organogenesis Holdings Inc. (NASDAQ: ORGO)
ALKS vs ORGO Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, ORGO has a market cap of 181.4M. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while ORGO trades at $1.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas ORGO's P/E ratio is 47.00. In terms of profitability, ALKS's ROE is +0.04%, compared to ORGO's ROE of -0.24%. Regarding short-term risk, ALKS is less volatile compared to ORGO. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check ORGO's competition here
Recro Pharma, Inc. (NASDAQ: REPH)
ALKS vs REPH Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas REPH's P/E ratio is -8.04. In terms of profitability, ALKS's ROE is +0.04%, compared to REPH's ROE of -0.22%. Regarding short-term risk, ALKS is less volatile compared to REPH. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check REPH's competition here
Journey Medical Corporation (NASDAQ: DERM)
ALKS vs DERM Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, DERM has a market cap of 169M. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while DERM trades at $6.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas DERM's P/E ratio is -27.91. In terms of profitability, ALKS's ROE is +0.04%, compared to DERM's ROE of -0.20%. Regarding short-term risk, ALKS is less volatile compared to DERM. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check DERM's competition here
Lifecore Biomedical, Inc. (NASDAQ: LFCR)
ALKS vs LFCR Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, LFCR has a market cap of 157.5M. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while LFCR trades at $4.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas LFCR's P/E ratio is -3.31. In terms of profitability, ALKS's ROE is +0.04%, compared to LFCR's ROE of -3.77%. Regarding short-term risk, ALKS is less volatile compared to LFCR. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check LFCR's competition here
Theratechnologies Inc. (NASDAQ: THTX)
ALKS vs THTX Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while THTX trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas THTX's P/E ratio is -28.83. In terms of profitability, ALKS's ROE is +0.04%, compared to THTX's ROE of +0.36%. Regarding short-term risk, ALKS is more volatile compared to THTX. This indicates higher risk in terms of short-term price fluctuations for ALKS.Check THTX's competition here
Organigram Global Inc. (NASDAQ: OGI)
ALKS vs OGI Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, OGI has a market cap of 154.9M. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while OGI trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas OGI's P/E ratio is 2.47. In terms of profitability, ALKS's ROE is +0.04%, compared to OGI's ROE of +0.21%. Regarding short-term risk, ALKS is less volatile compared to OGI. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check OGI's competition here
Assertio Holdings, Inc. (NASDAQ: ASRT)
ALKS vs ASRT Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, ASRT has a market cap of 151.9M. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while ASRT trades at $23.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas ASRT's P/E ratio is -7.10. In terms of profitability, ALKS's ROE is +0.04%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, ALKS is more volatile compared to ASRT. This indicates higher risk in terms of short-term price fluctuations for ALKS.Check ASRT's competition here
Societal CDMO, Inc. (NASDAQ: SCTL)
ALKS vs SCTL Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas SCTL's P/E ratio is -7.86. In terms of profitability, ALKS's ROE is +0.04%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, ALKS is more volatile compared to SCTL. This indicates higher risk in terms of short-term price fluctuations for ALKS.Check SCTL's competition here
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX)
ALKS vs CPIX Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, CPIX has a market cap of 114M. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while CPIX trades at $7.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas CPIX's P/E ratio is -19.02. In terms of profitability, ALKS's ROE is +0.04%, compared to CPIX's ROE of -0.47%. Regarding short-term risk, ALKS is less volatile compared to CPIX. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check CPIX's competition here
Procaps Group S.A. (NASDAQ: PROC)
ALKS vs PROC Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas PROC's P/E ratio is 1.53. In terms of profitability, ALKS's ROE is +0.04%, compared to PROC's ROE of -2.22%. Regarding short-term risk, ALKS is more volatile compared to PROC. This indicates higher risk in terms of short-term price fluctuations for ALKS.Check PROC's competition here
OptiNose, Inc. (NASDAQ: OPTN)
ALKS vs OPTN Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas OPTN's P/E ratio is -4.42. In terms of profitability, ALKS's ROE is +0.04%, compared to OPTN's ROE of +0.34%. Regarding short-term risk, ALKS is more volatile compared to OPTN. This indicates higher risk in terms of short-term price fluctuations for ALKS.Check OPTN's competition here
Zomedica Corp. (AMEX: ZOM)
ALKS vs ZOM Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas ZOM's P/E ratio is -1.62. In terms of profitability, ALKS's ROE is +0.04%, compared to ZOM's ROE of -0.17%. Regarding short-term risk, ALKS is less volatile compared to ZOM. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check ZOM's competition here
BGM Group Ltd. (NASDAQ: BGM)
ALKS vs BGM Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, BGM has a market cap of 91.4M. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while BGM trades at $0.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas BGM's P/E ratio is -1.50. In terms of profitability, ALKS's ROE is +0.04%, compared to BGM's ROE of -0.05%. Regarding short-term risk, ALKS is less volatile compared to BGM. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check BGM's competition here
Upexi, Inc. (NASDAQ: GRVI)
ALKS vs GRVI Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas GRVI's P/E ratio is 26.05. In terms of profitability, ALKS's ROE is +0.04%, compared to GRVI's ROE of -4.51%. Regarding short-term risk, ALKS is less volatile compared to GRVI. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check GRVI's competition here
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE)
ALKS vs ZYNE Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, ALKS's ROE is +0.04%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, ALKS is less volatile compared to ZYNE. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check ZYNE's competition here
Silver Spike Investment Corp. (NASDAQ: SSIC)
ALKS vs SSIC Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas SSIC's P/E ratio is 11.93. In terms of profitability, ALKS's ROE is +0.04%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, ALKS is less volatile compared to SSIC. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check SSIC's competition here
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT)
ALKS vs ZYBT Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, ZYBT has a market cap of 63M. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while ZYBT trades at $1.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas ZYBT's P/E ratio is -6.47. In terms of profitability, ALKS's ROE is +0.04%, compared to ZYBT's ROE of -0.27%. Regarding short-term risk, ALKS is less volatile compared to ZYBT. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check ZYBT's competition here
InterCure Ltd. (NASDAQ: INCR)
ALKS vs INCR Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, INCR has a market cap of 61.5M. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while INCR trades at $5.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas INCR's P/E ratio is -4.98. In terms of profitability, ALKS's ROE is +0.04%, compared to INCR's ROE of -0.09%. Regarding short-term risk, ALKS is less volatile compared to INCR. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check INCR's competition here
The Valens Company Inc. (NASDAQ: VLNS)
ALKS vs VLNS Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas VLNS's P/E ratio is -1.03. In terms of profitability, ALKS's ROE is +0.04%, compared to VLNS's ROE of N/A. Regarding short-term risk, ALKS is less volatile compared to VLNS. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check VLNS's competition here
Talphera, Inc. (NASDAQ: TLPH)
ALKS vs TLPH Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, TLPH has a market cap of 61.2M. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while TLPH trades at $1.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas TLPH's P/E ratio is -3.81. In terms of profitability, ALKS's ROE is +0.04%, compared to TLPH's ROE of -0.87%. Regarding short-term risk, ALKS is less volatile compared to TLPH. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check TLPH's competition here
DURECT Corporation (NASDAQ: DRRX)
ALKS vs DRRX Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while DRRX trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas DRRX's P/E ratio is -4.44. In terms of profitability, ALKS's ROE is +0.04%, compared to DRRX's ROE of -1.40%. Regarding short-term risk, ALKS is more volatile compared to DRRX. This indicates higher risk in terms of short-term price fluctuations for ALKS.Check DRRX's competition here
Jupiter Wellness, Inc. (NASDAQ: JUPW)
ALKS vs JUPW Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas JUPW's P/E ratio is -2.41. In terms of profitability, ALKS's ROE is +0.04%, compared to JUPW's ROE of -3.04%. Regarding short-term risk, ALKS is less volatile compared to JUPW. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check JUPW's competition here
Qilian International Holding Group Limited (NASDAQ: QLI)
ALKS vs QLI Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas QLI's P/E ratio is -4.92. In terms of profitability, ALKS's ROE is +0.04%, compared to QLI's ROE of -0.16%. Regarding short-term risk, ALKS is more volatile compared to QLI. This indicates higher risk in terms of short-term price fluctuations for ALKS.Check QLI's competition here
Rockwell Medical, Inc. (NASDAQ: RMTI)
ALKS vs RMTI Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, RMTI has a market cap of 33M. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while RMTI trades at $8.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas RMTI's P/E ratio is -6.25. In terms of profitability, ALKS's ROE is +0.04%, compared to RMTI's ROE of -0.14%. Regarding short-term risk, ALKS is less volatile compared to RMTI. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check RMTI's competition here
HEXO Corp. (NASDAQ: HEXO)
ALKS vs HEXO Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas HEXO's P/E ratio is -0.26. In terms of profitability, ALKS's ROE is +0.04%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, ALKS is less volatile compared to HEXO. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check HEXO's competition here
China Pharma Holdings, Inc. (AMEX: CPHI)
ALKS vs CPHI Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, CPHI has a market cap of 30.6M. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while CPHI trades at $0.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas CPHI's P/E ratio is -1.76. In terms of profitability, ALKS's ROE is +0.04%, compared to CPHI's ROE of -0.17%. Regarding short-term risk, ALKS is less volatile compared to CPHI. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check CPHI's competition here
Aytu BioPharma, Inc. (NASDAQ: AYTU)
ALKS vs AYTU Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, AYTU has a market cap of 24.5M. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while AYTU trades at $2.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas AYTU's P/E ratio is -0.50. In terms of profitability, ALKS's ROE is +0.04%, compared to AYTU's ROE of -0.53%. Regarding short-term risk, ALKS is less volatile compared to AYTU. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check AYTU's competition here
TherapeuticsMD, Inc. (NASDAQ: TXMD)
ALKS vs TXMD Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, TXMD has a market cap of 23.7M. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while TXMD trades at $2.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas TXMD's P/E ratio is 104.43. In terms of profitability, ALKS's ROE is +0.04%, compared to TXMD's ROE of -0.01%. Regarding short-term risk, ALKS is less volatile compared to TXMD. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check TXMD's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTH)
ALKS vs CYTH Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas CYTH's P/E ratio is -0.80. In terms of profitability, ALKS's ROE is +0.04%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, ALKS is more volatile compared to CYTH. This indicates higher risk in terms of short-term price fluctuations for ALKS.Check CYTH's competition here
Evoke Pharma, Inc. (NASDAQ: EVOK)
ALKS vs EVOK Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while EVOK trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas EVOK's P/E ratio is -7.97. In terms of profitability, ALKS's ROE is +0.04%, compared to EVOK's ROE of -0.89%. Regarding short-term risk, ALKS is more volatile compared to EVOK. This indicates higher risk in terms of short-term price fluctuations for ALKS.Check EVOK's competition here
Optimi Health Corp. (NASDAQ: OPTH)
ALKS vs OPTH Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, OPTH has a market cap of 15.5M. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while OPTH trades at $4.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas OPTH's P/E ratio is -3.35. In terms of profitability, ALKS's ROE is +0.04%, compared to OPTH's ROE of -0.90%. Regarding short-term risk, ALKS is less volatile compared to OPTH. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check OPTH's competition here
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)
ALKS vs ACRX Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas ACRX's P/E ratio is -0.31. In terms of profitability, ALKS's ROE is +0.04%, compared to ACRX's ROE of -0.87%. Regarding short-term risk, ALKS is less volatile compared to ACRX. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check ACRX's competition here
Caring Brands, Inc. (NASDAQ: CABR)
ALKS vs CABR Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, CABR has a market cap of 10.8M. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while CABR trades at $1.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas CABR's P/E ratio is -1.53. In terms of profitability, ALKS's ROE is +0.04%, compared to CABR's ROE of -3.86%. Regarding short-term risk, ALKS is less volatile compared to CABR. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check CABR's competition here
Agile Therapeutics, Inc. (NASDAQ: AGRX)
ALKS vs AGRX Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas AGRX's P/E ratio is -0.89. In terms of profitability, ALKS's ROE is +0.04%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, ALKS is less volatile compared to AGRX. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check AGRX's competition here
Neoleukin Therapeutics, Inc. (NASDAQ: NLTX)
ALKS vs NLTX Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas NLTX's P/E ratio is -0.28. In terms of profitability, ALKS's ROE is +0.04%, compared to NLTX's ROE of -0.45%. Regarding short-term risk, ALKS is less volatile compared to NLTX. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check NLTX's competition here
Lannett Company, Inc. (NYSE: LCI)
ALKS vs LCI Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas LCI's P/E ratio is -0.04. In terms of profitability, ALKS's ROE is +0.04%, compared to LCI's ROE of +1.66%. Regarding short-term risk, ALKS is less volatile compared to LCI. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check LCI's competition here
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP)
ALKS vs ADMP Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas ADMP's P/E ratio is -0.08. In terms of profitability, ALKS's ROE is +0.04%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, ALKS is less volatile compared to ADMP. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check ADMP's competition here
Gelteq Limited Ordinary Shares (NASDAQ: GELS)
ALKS vs GELS Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, GELS has a market cap of 5M. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while GELS trades at $0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas GELS's P/E ratio is -1.09. In terms of profitability, ALKS's ROE is +0.04%, compared to GELS's ROE of -0.25%. Regarding short-term risk, ALKS is less volatile compared to GELS. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check GELS's competition here
cbdMD, Inc. (AMEX: YCBD)
ALKS vs YCBD Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, YCBD has a market cap of 4.8M. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while YCBD trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas YCBD's P/E ratio is -1.13. In terms of profitability, ALKS's ROE is +0.04%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, ALKS is less volatile compared to YCBD. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check YCBD's competition here
Mallinckrodt plc (AMEX: MNK)
ALKS vs MNK Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while MNK trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas MNK's P/E ratio is -0.44. In terms of profitability, ALKS's ROE is +0.04%, compared to MNK's ROE of -0.36%. Regarding short-term risk, ALKS is less volatile compared to MNK. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check MNK's competition here
Flora Growth Corp. (NASDAQ: FLGC)
ALKS vs FLGC Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while FLGC trades at $7.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas FLGC's P/E ratio is -0.19. In terms of profitability, ALKS's ROE is +0.04%, compared to FLGC's ROE of -3.03%. Regarding short-term risk, ALKS is less volatile compared to FLGC. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check FLGC's competition here
Universe Pharmaceuticals Inc. (NASDAQ: UPC)
ALKS vs UPC Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, UPC has a market cap of 2.9M. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while UPC trades at $4.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas UPC's P/E ratio is -0.57. In terms of profitability, ALKS's ROE is +0.04%, compared to UPC's ROE of -0.03%. Regarding short-term risk, ALKS is less volatile compared to UPC. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check UPC's competition here
PLx Pharma Inc. (NASDAQ: PLXP)
ALKS vs PLXP Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while PLXP trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas PLXP's P/E ratio is -0.22. In terms of profitability, ALKS's ROE is +0.04%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, ALKS is less volatile compared to PLXP. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check PLXP's competition here
InMed Pharmaceuticals Inc. (NASDAQ: INM)
ALKS vs INM Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, INM has a market cap of 2.5M. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while INM trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas INM's P/E ratio is -0.25. In terms of profitability, ALKS's ROE is +0.04%, compared to INM's ROE of -1.35%. Regarding short-term risk, ALKS is less volatile compared to INM. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check INM's competition here
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH)
ALKS vs SHPH Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, SHPH has a market cap of 2.3M. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while SHPH trades at $4.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas SHPH's P/E ratio is -0.19. In terms of profitability, ALKS's ROE is +0.04%, compared to SHPH's ROE of -1.57%. Regarding short-term risk, ALKS is less volatile compared to SHPH. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check SHPH's competition here
Athenex, Inc. (NASDAQ: ATNX)
ALKS vs ATNX Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while ATNX trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas ATNX's P/E ratio is -0.02. In terms of profitability, ALKS's ROE is +0.04%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, ALKS is more volatile compared to ATNX. This indicates higher risk in terms of short-term price fluctuations for ALKS.Check ATNX's competition here
Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA)
ALKS vs SNOA Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, SNOA has a market cap of 2.1M. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while SNOA trades at $1.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas SNOA's P/E ratio is -1.14. In terms of profitability, ALKS's ROE is +0.04%, compared to SNOA's ROE of -0.54%. Regarding short-term risk, ALKS is less volatile compared to SNOA. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check SNOA's competition here
Sunshine Biopharma, Inc. (NASDAQ: SBFM)
ALKS vs SBFM Comparison September 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 6.9B. In comparison, SBFM has a market cap of 2M. Regarding current trading prices, ALKS is priced at $40.85 on the NASDAQ, while SBFM trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 43.00, whereas SBFM's P/E ratio is -0.14. In terms of profitability, ALKS's ROE is +0.04%, compared to SBFM's ROE of -0.24%. Regarding short-term risk, ALKS is less volatile compared to SBFM. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check SBFM's competition here